Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 3/2018

01-03-2018 | Original paper

Glucosamine use and risk of colorectal cancer: results from the Cancer Prevention Study II Nutrition Cohort

Authors: Elizabeth D. Kantor, Christina C. Newton, Edward L. Giovannucci, Marjorie L. McCullough, Peter T. Campbell, Eric J. Jacobs

Published in: Cancer Causes & Control | Issue 3/2018

Login to get access

Abstract

Purpose

Use of glucosamine supplements has been associated with reduced risk of colorectal cancer (CRC) in previous studies; however, information on this association remains limited.

Methods

We examined the association between glucosamine use and CRC risk among 113,067 men and women in the Cancer Prevention Study II Nutrition Cohort. Glucosamine use was first reported in 2001 and updated every 2 years thereafter. Participants were followed from 2001 through June of 2011, during which time 1440 cases of CRC occurred.

Results

As has been observed in prior studies, current use of glucosamine, modeled using a time-varying exposure, was associated with lower risk of CRC (HR 0.83; 95% CI 0.71–0.97) compared to never use. However, for reasons that are unclear, this reduction in risk was observed for shorter-duration use (HR 0.68; 95% CI 0.52–0.87 for current users with ≤ 2 years use) rather than longer-duration use (HR 0.90; 95% CI 0.72–1.13 for current users with 3 to < 6 years of use; HR 0.99; 95% CI 0.76–1.29 for current users with ≥ 6 years of use).

Conclusions

Further research is needed to better understand the association between glucosamine use and risk of CRC, and how this association may vary by duration of use.
Appendix
Available only for authorised users
Literature
1.
Kantor ED, Rehm CD, Du M, White E, Giovannucci EL (2016) Trends in dietary supplement use among US adults from 1999 to 2012. JAMA 316(14):1464–1474CrossRef
2.
Clegg DO, Reda DJ, Harris CL, Klein MA, O’Dell JR, Hooper MM et al (2006) Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 354(8):795–808CrossRef
3.
McAlindon TE, LaValley MP, Gulin JP, Felson DT (2000) Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 283(11):1469–1475CrossRef
4.
Satia JA, Littman A, Slatore CG, Galanko JA, White E (2009) Associations of herbal and specialty supplements with lung and colorectal cancer risk in the VITamins and lifestyle study. Cancer Epidemiol Biomark Prev 18(5):1419–1428CrossRef
5.
Kantor ED, Lampe JW, Peters U, Shen DD, Vaughan TL, White E (2013) Use of glucosamine and chondroitin supplements and risk of colorectal cancer. Cancer Causes Control 24(6):1137–1146CrossRef
6.
Kantor ED, Zhang X, Wu K, Signorello LB, Chan AT, Fuchs CS et al (2015) Use of glucosamine and chondroitin supplements in relation to risk of colorectal cancer: results from the Nurses’ Health Study and Health Professionals follow-up study. Int J Cancer 139(9):1949–1957CrossRef
7.
Largo R, Alvarez-Soria MA, Diez-Ortego I, Calvo E, Sanchez-Pernaute O, Egido J et al (2003) Glucosamine inhibits IL-1beta-induced NFkappaB activation in human osteoarthritic chondrocytes. Osteoarthr Cartil 11(4):290–298CrossRef
8.
Sakai S, Sugawara T, Kishi T, Yanagimoto K, Hirata T (2010) Effect of glucosamine and related compounds on the degranulation of mast cells and ear swelling induced by dinitrofluorobenzene in mice. Life Sci 86(9–10):337–343CrossRef
9.
Wu YL, Kou YR, Ou HL, Chien HY, Chuang KH, Liu HH et al (2010) Glucosamine regulation of LPS-mediated inflammation in human bronchial epithelial cells. Eur J Pharmacol 635(1–3):219–226CrossRef
10.
Yomogida S, Hua J, Sakamoto K, Nagaoka I (2008) Glucosamine suppresses interleukin-8 production and ICAM-1 expression by TNF-alpha-stimulated human colonic epithelial HT-29 cells. Int J Mol Med 22(2):205–211PubMed
11.
Neil KM, Orth MW, Coussens PM, Chan PS, Caron JP (2005) Effects of glucosamine and chondroitin sulfate on mediators of osteoarthritis in cultured equine chondrocytes stimulated by use of recombinant equine interleukin-1beta. Am J Vet Res 66(11):1861–1869CrossRef
12.
Hong H, Park YK, Choi MS, Ryu NH, Song DK, Suh SI et al (2009) Differential down-regulation of COX-2 and MMP-13 in human skin fibroblasts by glucosamine-hydrochloride. J Dermatol Sci 56(1):43–50CrossRef
13.
Nakamura H, Shibakawa A, Tanaka M, Kato T, Nishioka K (2004) Effects of glucosamine hydrochloride on the production of prostaglandin E2, nitric oxide and metalloproteases by chondrocytes and synoviocytes in osteoarthritis. Clin Exp Rheumatol 22(3):293–299PubMed
14.
Rajapakse N, Kim MM, Mendis E, Kim SK (2008) Inhibition of inducible nitric oxide synthase and cyclooxygenase-2 in lipopolysaccharide-stimulated RAW264.7 cells by carboxybutyrylated glucosamine takes place via down-regulation of mitogen-activated protein kinase-mediated nuclear factor-kappaB signaling. Immunology 123(3):348–357CrossRef
15.
Gouze JN, Bordji K, Gulberti S, Terlain B, Netter P, Magdalou J et al (2001) Interleukin-1beta down-regulates the expression of glucuronosyltransferase I, a key enzyme priming glycosaminoglycan biosynthesis: influence of glucosamine on interleukin-1beta-mediated effects in rat chondrocytes. Arthritis Rheumatol 44(2):351–360CrossRef
16.
Largo R, Martinez-Calatrava MJ, Sanchez-Pernaute O, Marcos ME, Moreno-Rubio J, Aparicio C et al (2009) Effect of a high dose of glucosamine on systemic and tissue inflammation in an experimental model of atherosclerosis aggravated by chronic arthritis. Am J Physiol Heart Circ Physiol 297(1):H268-276CrossRef
17.
Azuma K, Osaki T, Wakuda T, Tsuka T, Imagawa T, Okamoto Y et al (2012) Suppressive effects of N-acetyl-D-glucosamine on rheumatoid arthritis mouse models. Inflammation 35(4):1462–1465CrossRef
18.
Hua J, Sakamoto K, Kikukawa T, Abe C, Kurosawa H, Nagaoka I (2007) Evaluation of the suppressive actions of glucosamine on the interleukin-1beta-mediated activation of synoviocytes. Inflamm Res 56(10):432–438CrossRef
19.
Arafa NM, Hamuda HM, Melek ST, Darwish SK (2013) The effectiveness of Echinacea extract or composite glucosamine, chondroitin and methyl sulfonyl methane supplements on acute and chronic rheumatoid arthritis rat model. Toxicol Ind Health 29(2):187–201CrossRef
20.
Chou MM, Vergnolle N, McDougall JJ, Wallace JL, Marty S, Teskey V et al (2005) Effects of chondroitin and glucosamine sulfate in a dietary bar formulation on inflammation, interleukin-1beta, matrix metalloproteinase-9, and cartilage damage in arthritis. Exp Biol Med 230(4):255–262CrossRef
21.
Yomogida S, Kojima Y, Tsutsumi-Ishii Y, Hua J, Sakamoto K, Nagaoka I (2008) Glucosamine, a naturally occurring amino monosaccharide, suppresses dextran sulfate sodium-induced colitis in rats. Int J Mol Med 22(3):317–323PubMed
22.
Bak YK, Lampe JW, Sung MK (2014) Effects of dietary supplementation of glucosamine sulfate on intestinal inflammation in a mouse model of experimental colitis. J Gastroenterol Hepatol 29(5):957–963CrossRef
23.
Kantor ED, Lampe JW, Navarro SL, Song X, Milne GL, White E (2014) Associations between glucosamine and chondroitin supplement use and biomarkers of systemic inflammation. J Altern Complement Med 20(6):479–485CrossRef
24.
Kantor ED, Lampe JW, Vaughan TL, Peters U, Rehm CD, White E (2012) Association between use of specialty dietary supplements and C-reactive protein concentrations. Am J Epidemiol 176(11):1002–1013CrossRef
25.
Navarro SL, White E, Kantor ED, Zhang Y, Rho J, Song X et al (2015) Randomized trial of glucosamine and chondroitin supplementation on inflammation and oxidative stress biomarkers and plasma proteomics profiles in healthy humans. PLoS ONE 10(2):e0117534CrossRef
26.
Hua J, Suguro S, Hirano S, Sakamoto K, Nagaoka I (2005) Preventive actions of a high dose of glucosamine on adjuvant arthritis in rats. Inflamm Res 54(3):127–132CrossRef
27.
Nakamura H, Nishioka K (2002) Effects of glucosamine/chondroitin supplement on osteoarthritis: involvement of PGE2 and YKL-40. J Rheum Joint Surg 21:175–184
28.
Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ (2004) C-reactive protein and the risk of incident colorectal cancer. JAMA 291(5):585–590CrossRef
29.
Cai Q, Gao YT, Chow WH, Shu XO, Yang G, Ji BT et al (2006) Prospective study of urinary prostaglandin E2 metabolite and colorectal cancer risk. J Clin Oncol 24(31):5010–5016CrossRef
30.
Wang S, Liu Z, Wang L, Zhang X (2009) NF-kappaB signaling pathway, inflammation and colorectal cancer. Cell Mol Immunol 6(5):327–334CrossRef
31.
Schottenfeld D, Beebe-Dimmer J (2006) Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer J Clin 56(2):69–83CrossRef
32.
Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP et al (2010) Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376(9754):1741–1750CrossRef
33.
Calle EE, Rodriguez C, Jacobs EJ, Almon ML, Chao A, McCullough ML et al (2002) The American Cancer Society Cancer Prevention Study II Nutrition Cohort: rationale, study design, and baseline characteristics. Cancer 94(9):2490–2501CrossRef
34.
Walter RB, Milano F, Brasky TM, White E (2011) Long-term use of acetaminophen, aspirin, and other nonsteroidal anti-inflammatory drugs and risk of hematologic malignancies: results from the prospective Vitamins and Lifestyle (VITAL) study. J Clin Oncol 29(17):2424–2431CrossRef
35.
Brasky TM, Moysich KB, Cohn DE, White E (2013) Non-steroidal anti-inflammatory drugs and endometrial cancer risk in the VITamins And Lifestyle (VITAL) cohort. Gynecol Oncol 128(1):113–119CrossRef
36.
Brasky TM, Lampe JW, Slatore CG, White E (2011) Use of glucosamine and chondroitin and lung cancer risk in the VITamins And Lifestyle (VITAL) cohort. Cancer Causes Control 22(9):1333–1342CrossRef
37.
Calle EE, Terrell DD (1993) Utility of the National Death Index for ascertainment of mortality among cancer prevention study II participants. Am J Epidemiol 137(2):235–241CrossRef
38.
Kleinbaum DG (1996) Survival analysis: a self-learning text. Springer, New YorkCrossRef
39.
Li Q, Withoff S, Verma IM (2005) Inflammation-associated cancer: NF-kappaB is the lynchpin. Trends Immunol 26(6):318–325CrossRef
40.
Kantor ED, Ulrich CM, Owen RW, Schmezer P, Neuhouser ML, Lampe JW et al (2013) Specialty supplement use and biologic measures of oxidative stress and DNA damage. Cancer Epidemiol Prev 22(12):2312–2322CrossRef
Metadata
Title
Glucosamine use and risk of colorectal cancer: results from the Cancer Prevention Study II Nutrition Cohort
Authors
Elizabeth D. Kantor
Christina C. Newton
Edward L. Giovannucci
Marjorie L. McCullough
Peter T. Campbell
Eric J. Jacobs
Publication date
01-03-2018
Publisher
Springer International Publishing
Published in
Cancer Causes & Control / Issue 3/2018
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-018-1003-6

Other articles of this Issue 3/2018

Cancer Causes & Control 3/2018 Go to the issue

Original paper

Heterogeneous impacts: adverse childhood experiences and cancer screening

Commentary

Geospatial approaches to cancer control and population sciences at the United States cancer centers

Brief report

Participatory implementation science to increase the impact of evidence-based cancer prevention and control

Brief report

Developing new age-specific prostate-specific antigen thresholds for testing for prostate cancer

Original paper

A risk prediction model to allow personalized screening for cervical cancer

Original paper

Demographic, presentation, and treatment factors and racial disparities in ovarian cancer hospitalization outcomes
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits